Language:

Role of Finerenone in the Treatment of Diabetic Kidney Disease: Patient Selection and Clinical Perspectives

Therapeutics and clinical risk management, 2022-07, Vol.18, p.753-760 [Peer Reviewed Journal]

COPYRIGHT 2022 Dove Medical Press Limited ;2022. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2022 Shaikh et al. 2022 Shaikh et al. ;ISSN: 1178-203X ;ISSN: 1176-6336 ;EISSN: 1178-203X ;DOI: 10.2147/TCRM.S325916 ;PMID: 35937973

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Role of Finerenone in the Treatment of Diabetic Kidney Disease: Patient Selection and Clinical Perspectives
Author: Shaikh, Aisha ; Ray, Justina ; Campbell, Kirk N
Subjects: Cardiac patients ; Cardiomyocytes ; Cardiovascular disease ; Cardiovascular diseases ; chronic kidney disease ; Chronic kidney failure ; Confidence intervals ; Creatinine ; Diabetes ; Diabetic retinopathy ; Drug dosages ; finerenone ; Gene expression ; Heart attacks ; Heart failure ; Hospitalization ; Hyperkalemia ; Inflammation ; Kidney diseases ; Metabolites ; Patients ; Peptides ; Regulatory approval ; Review ; Stroke ; Type 2 diabetes
Is Part Of: Therapeutics and clinical risk management, 2022-07, Vol.18, p.753-760
Description: Diabetes is the leading cause of chronic and end stage kidney disease globally. Despite recent advances in therapies for diabetic kidney disease (DKD), there remains a critical need for additional options to improve renal and cardiovascular outcomes. Mineralocorticoid overactivation contributes to inflammation and fibrosis which in turn leads to progression of DKD. Finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, has shown promising cardiac and renoprotective benefits in DKD. The utility of finerenone in the real world will require appropriate patient selection and patient monitoring by clinicians. Keywords: finerenone, diabetes, chronic kidney disease
Publisher: Macclesfield: Dove Medical Press Limited
Language: English
Identifier: ISSN: 1178-203X
ISSN: 1176-6336
EISSN: 1178-203X
DOI: 10.2147/TCRM.S325916
PMID: 35937973
Source: Geneva Foundation Free Medical Journals at publisher websites
AUTh Library subscriptions: ProQuest Central
DOVE Medical Press OA Journals
PubMed Central
DOAJ Directory of Open Access Journals

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Role of Finerenone in the Treatment of Diabetic Kidney Disease: Patient Selection and Clinical Perspectives

Searching Remote Databases, Please Wait